Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Luminex Awarded $11 Million Contract by DTRA

Published: Tuesday, August 14, 2012
Last Updated: Tuesday, August 14, 2012
Bookmark and Share
Department of defense award accelerates development of Luminex bio-threat detection technology program.

Luminex Corporation has announced that it has been awarded a contract worth up to $11.6 million over three and a half years.

The contract will fund development of a prototype instrument that is highly portable, field-deployable diagnostic tool capable of rapid detection of biothreat agents and patient response biomarkers indicative of systemic disease.

This hand-held system will detect both protein and nucleic acid targets to aid diagnosis of Systemic Inflammatory Response Syndrome (SIRS), a consequence of blood infection in conventional combat, biowarfare and combat operations in developing and resource-limited areas.

Infection and disease caused by biowarfare agents carry the very real threat of catastrophic illness and death of military and civilian personnel.

The pathophysiology of candidate biowarfare microbes is varied and may involve multiple organ systems, but there are some common features associated with bloodstream infection that permit the development of a sensitive diagnostic test that not only identifies biowarfare pathogens but also can be use outside of an executed bioagent attack.

"Rapid response and informed decisions on therapeutic options are critical in managing biothreat agent exposure," said Amy Altman, Ph.D., vice president Luminex Biodefense.

Altman continued, "The flexibility and scalability of our multiplexing technology allow for the measurement of RNA, DNA and proteins with the same system, aiding rapid and accurate diagnosis of these severe conditions. Development of a field deployable device using our technology has the potential to provide significant advancement in biothreat detection."

"Luminex is highly committed to success in the area of biodefense. We are pleased that DTRA recognizes the potential contribution our technology can make in the detection of biothreat agents," said Patrick J. Balthrop, president and CEO of Luminex.

Balthrop continued, "We look forward to collaborating on this important initiative by developing innovative solutions for combating biothreat agents and protecting the safety of people everywhere."

The contract awarded to Luminex supports The Chemical and Biological Defense Initiative Fund (CMB-DIAGB2) U.S. Department of Defense's Defense Threat Reduction Agency (DTRA). Solicitation was issued for full and open competition and 56 proposals were received.

Established in 1998, the Defense Threat Reduction Agency (DTRA) provides the Department of Defense's core intellectual, technical and operational support expertise for countering threats posed by weapons of mass destruction (chemical, biological, radiological, and nuclear) and high-yield explosives.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Luminex Technology Selected by Assurex Health
xTAG® Technology to aid in GeneSight® precision medicine test.
Saturday, March 21, 2015
Pioneering Human Protein Atlas Project Achieves a Major Milestone
Project leverages Luminex's xMAP® technology for biobank profiling research.
Thursday, March 20, 2014
Luminex Receives FDA and European Clearance for xTAG® CYP2C19 Kit
New cytochrome P450 2C19 assay helps physicians optimize individual patient care.
Tuesday, September 24, 2013
Luminex Receives FDA and European Clearance for New Version of xTAG® CYP2D6 Kit
Luminex submits xTAG® CYP2C19 kit to FDA for review.
Tuesday, July 16, 2013
Merck and Luminex Corporation Enter Agreement
Collaboration to support patient selection for the clinical development of MK-8931, Merck’s lead investigational medicine for Alzheimer’s disease.
Thursday, July 04, 2013
Luminex Corporation and EMD Millipore Extend Their Global Supply and Distribution Agreement
This long-term agreement strengthens the partnership and facilitates development of life science and protein assays.
Thursday, May 30, 2013
Luminex Corporation Expands Life Science and Biodefense Groups
Two dedicated groups advance Luminex leadership in scientific research and public safety.
Thursday, April 26, 2012
Luminex and Partners HealthCare Announce Collaboration Agreement
Collaborative efforts aimed at translating biomarker discoveries into novel molecular diagnostic tests.
Wednesday, February 16, 2011
Luminex Corporation Launches New FDA Cleared Pharmacogenetic Diagnostic Test
xTAG® CYP2D6 kit can assist physicians in improving patient care by helping to determine a personalized therapeutic strategy.
Thursday, November 18, 2010
Luminex Corporation and ViroNovative Announce License Agreement for Human Metapneumovirus Rights
Luminex gains worldwide rights to use ViroNovative's human metapneumovirus intellectual property in the xTAG Respiratory Viral Panel.
Tuesday, July 15, 2008
Luminex Receives U.S. Food and Drug Administration Clearance for xTAG™ Respiratory Viral Panel
The Company has designed the test to simultaneously detect the most prevalent respiratory viruses.
Friday, January 04, 2008
Luminex Licenses Cystic Fibrosis Gene Patent from John Hopkins University
Luminex’s TAG-IT™ cystic fibrosis kits to include rights to university's proprietary genetic markers.
Tuesday, April 24, 2007
Luminex Hosts Planet xMAP Technology Symposium
The symposium includes presentations and workshops utilizing Luminex's xMAP® technology in clinical diagnostics and life sciences research.
Tuesday, April 25, 2006
Scientific News
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Oxitec ‘Self-Limiting Gene’ Offers Hope for Controlling Invasive Moth
A new pesticide-free and environmentally-friendly way to control insect pests has moved ahead with the publication of results showing that Oxitec diamondback moths (DBM) with a ‘self-limiting gene’ can dramatically reduce populations of DBM.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!